ReviewCurrent opinion in oncology2017
Put away your microscopes: the ependymoma molecular era has begun.
Review in Current opinion in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A brief history of ependymoma.Neuro-oncology · 2026Review
- Optimizing outcomes in intracranial ependymoma: a contemporary review.Frontiers in oncology · 2025Review
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Case Report: Clinical awareness about the effect of laser interstitial thermal therapy on pediatric high-grade brain tumors after radiotherapy.Frontiers in surgery · 2024Article
- Somatic structural variation signatures in pediatric brain tumors.Cell reports · 2023Article
- Somatic structural variation signatures in pediatric brain tumors.medRxiv : the preprint server for health sciences · 2023Article
- History of research concerning the ependyma: a view from inside the human brain.Frontiers in cellular neuroscience · 2023Review
- Article
- Citation analysis of the most influential ependymoma research articles illustrates improved knowledge of the molecular biology of ependymoma.Neurosurgical review · 2022Review
- Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.Frontiers in oncology · 2022Review
- Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era.Korean journal of radiology · 2021Review
- DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.Clinical epigenetics · 2021Article
- Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.Neuro-oncology · 2021Article
- Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.Frontiers in oncology · 2021Review
- Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor anJCO precision oncology · 2021Article
- Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016.Neuro-oncology practice · 2020Article
- Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Intracranial ependymomas: molecular insights and translation to treatment.Brain pathology (Zurich, Switzerland) · 2020Review
- New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.Scientific reports · 2019Article
- Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era.Journal of Korean Neurosurgical Society · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewTo synthesize, integrate, and comment on recent research developments to our understanding of the molecular basis of ependymoma (EPN), and to place this in context with current treatment and research efforts. RECENT
findingsOur recent understanding of the histologically defined molecular entity EPN has rapidly advanced through genomic, transcriptomic, and epigenomic profiling studies. SUMMARY: These advancements lay the groundwork for development of future EPN biomarkers, models, and therapeutics. Our review discusses these discoveries and their impact on our clinical understanding of this disease. Lastly, we offer insight into clinical and research areas requiring further validation, and open questions remaining in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.